Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This breakthrough signals China's growing role in global biotech, though domestic skepticism about homegrown medicines persists. Akeso's drug has gained approval in China and plans for worldwide trials are underway to further prove its efficacy.